Novartis’s tislelizumab phase-III trial data shows survival results in esophageal cancer EP News Bureau Jul 5, 2022 First-line tislelizumab plus chemotherapy showed median Overall Survival (OS) of 17.2 months versus 10.6 months for chemotherapy…
